Home » Santarus Patents on Zegerid Ruled Invalid
Santarus Patents on Zegerid Ruled Invalid
A federal court has ruled that five patents on Santarus’ heartburn drug Zegerid are invalid due to obviousness, a move that could pave the way
for generic versions of the drug to enter the market. The company’s patents on Zegerid (omeprazole/sodium bicarbonate) were challenged by generic
drugmaker Par Pharmaceutical, according to a filing with the U.S. District Court for the District of Delaware. Santarus says it plans to appeal. The Zegerid
patents expire July 15, 2016.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May